Cargando…

Chitosan Oligosaccharides Regulate the Occurrence and Development of Enteritis in a Human Gut-On-a-Chip

Past studies on the protective effects of chitosan oligosaccharides (COS) on inflammatory bowel disease (IBD) commonly rely on animal models, because traditional cell culture systems couldn’t faithfully mimic human intestinal physiology. Here a novel human gut-on-a-chip microsystem was established t...

Descripción completa

Detalles Bibliográficos
Autores principales: Jing, Bolin, Xia, Kun, Zhang, Chen, Jiao, Siming, Zhu, Limeng, Wei, Jinhua, Wang, Zhuo A., Chen, Nannan, Tu, Pengfei, Li, Jianjun, Du, Yuguang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9086312/
https://www.ncbi.nlm.nih.gov/pubmed/35557948
http://dx.doi.org/10.3389/fcell.2022.877892
_version_ 1784703969947287552
author Jing, Bolin
Xia, Kun
Zhang, Chen
Jiao, Siming
Zhu, Limeng
Wei, Jinhua
Wang, Zhuo A.
Chen, Nannan
Tu, Pengfei
Li, Jianjun
Du, Yuguang
author_facet Jing, Bolin
Xia, Kun
Zhang, Chen
Jiao, Siming
Zhu, Limeng
Wei, Jinhua
Wang, Zhuo A.
Chen, Nannan
Tu, Pengfei
Li, Jianjun
Du, Yuguang
author_sort Jing, Bolin
collection PubMed
description Past studies on the protective effects of chitosan oligosaccharides (COS) on inflammatory bowel disease (IBD) commonly rely on animal models, because traditional cell culture systems couldn’t faithfully mimic human intestinal physiology. Here a novel human gut-on-a-chip microsystem was established to further explore the regulatory effects of COS on the occurrence and development of human enteritis. By constructing an intestinal injury model caused by dextran sodium sulfate (DSS) on the chip, this study proved that COS can reduce intestinal epithelial injury by promoting the expression of the mucous layer for the first time. By establishing an inflammatory bowel disease model on the chip caused by E. coli 11775, this study demonstrated that COS can protect the intestinal epithelial barrier and vascular endothelial barrier by inhibiting the adhesion and invasion of E. coli 11775 for the first time. In addition, similar to the results in vivo, COS can decrease the inflammatory response by reducing the expression of toll-like receptor 4 protein and reducing the nuclear DNA binding rate of nuclear factor kappa-B protein on this chip. In summary, COS can be used as a potential drug to treat human IBD and the human gut-on-a-chip would be used as a platform for quick screening drugs to treat human IBD in future.
format Online
Article
Text
id pubmed-9086312
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90863122022-05-11 Chitosan Oligosaccharides Regulate the Occurrence and Development of Enteritis in a Human Gut-On-a-Chip Jing, Bolin Xia, Kun Zhang, Chen Jiao, Siming Zhu, Limeng Wei, Jinhua Wang, Zhuo A. Chen, Nannan Tu, Pengfei Li, Jianjun Du, Yuguang Front Cell Dev Biol Cell and Developmental Biology Past studies on the protective effects of chitosan oligosaccharides (COS) on inflammatory bowel disease (IBD) commonly rely on animal models, because traditional cell culture systems couldn’t faithfully mimic human intestinal physiology. Here a novel human gut-on-a-chip microsystem was established to further explore the regulatory effects of COS on the occurrence and development of human enteritis. By constructing an intestinal injury model caused by dextran sodium sulfate (DSS) on the chip, this study proved that COS can reduce intestinal epithelial injury by promoting the expression of the mucous layer for the first time. By establishing an inflammatory bowel disease model on the chip caused by E. coli 11775, this study demonstrated that COS can protect the intestinal epithelial barrier and vascular endothelial barrier by inhibiting the adhesion and invasion of E. coli 11775 for the first time. In addition, similar to the results in vivo, COS can decrease the inflammatory response by reducing the expression of toll-like receptor 4 protein and reducing the nuclear DNA binding rate of nuclear factor kappa-B protein on this chip. In summary, COS can be used as a potential drug to treat human IBD and the human gut-on-a-chip would be used as a platform for quick screening drugs to treat human IBD in future. Frontiers Media S.A. 2022-04-26 /pmc/articles/PMC9086312/ /pubmed/35557948 http://dx.doi.org/10.3389/fcell.2022.877892 Text en Copyright © 2022 Jing, Xia, Zhang, Jiao, Zhu, Wei, Wang, Chen, Tu, Li and Du. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cell and Developmental Biology
Jing, Bolin
Xia, Kun
Zhang, Chen
Jiao, Siming
Zhu, Limeng
Wei, Jinhua
Wang, Zhuo A.
Chen, Nannan
Tu, Pengfei
Li, Jianjun
Du, Yuguang
Chitosan Oligosaccharides Regulate the Occurrence and Development of Enteritis in a Human Gut-On-a-Chip
title Chitosan Oligosaccharides Regulate the Occurrence and Development of Enteritis in a Human Gut-On-a-Chip
title_full Chitosan Oligosaccharides Regulate the Occurrence and Development of Enteritis in a Human Gut-On-a-Chip
title_fullStr Chitosan Oligosaccharides Regulate the Occurrence and Development of Enteritis in a Human Gut-On-a-Chip
title_full_unstemmed Chitosan Oligosaccharides Regulate the Occurrence and Development of Enteritis in a Human Gut-On-a-Chip
title_short Chitosan Oligosaccharides Regulate the Occurrence and Development of Enteritis in a Human Gut-On-a-Chip
title_sort chitosan oligosaccharides regulate the occurrence and development of enteritis in a human gut-on-a-chip
topic Cell and Developmental Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9086312/
https://www.ncbi.nlm.nih.gov/pubmed/35557948
http://dx.doi.org/10.3389/fcell.2022.877892
work_keys_str_mv AT jingbolin chitosanoligosaccharidesregulatetheoccurrenceanddevelopmentofenteritisinahumangutonachip
AT xiakun chitosanoligosaccharidesregulatetheoccurrenceanddevelopmentofenteritisinahumangutonachip
AT zhangchen chitosanoligosaccharidesregulatetheoccurrenceanddevelopmentofenteritisinahumangutonachip
AT jiaosiming chitosanoligosaccharidesregulatetheoccurrenceanddevelopmentofenteritisinahumangutonachip
AT zhulimeng chitosanoligosaccharidesregulatetheoccurrenceanddevelopmentofenteritisinahumangutonachip
AT weijinhua chitosanoligosaccharidesregulatetheoccurrenceanddevelopmentofenteritisinahumangutonachip
AT wangzhuoa chitosanoligosaccharidesregulatetheoccurrenceanddevelopmentofenteritisinahumangutonachip
AT chennannan chitosanoligosaccharidesregulatetheoccurrenceanddevelopmentofenteritisinahumangutonachip
AT tupengfei chitosanoligosaccharidesregulatetheoccurrenceanddevelopmentofenteritisinahumangutonachip
AT lijianjun chitosanoligosaccharidesregulatetheoccurrenceanddevelopmentofenteritisinahumangutonachip
AT duyuguang chitosanoligosaccharidesregulatetheoccurrenceanddevelopmentofenteritisinahumangutonachip